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Introduction
In contrast with the numerous controlled trials conducted
in polyarticular or systemic juvenile idiopathic arthritis
(JIA), little evidence-based information is available for oli-
goarticular JIA. As a result, the management of children
with this subtype, which is the most prevalent in Western
countries, is largely empiric. Intra-articular corticosteroid
(IAC) injection is the therapy of first choice for oligoar-
thritis in many pediatric rheumatology centers. However,
although IAC injections are usually highly efficacious,
relapses of synovitis are common and sometimes occur
only a few months after the procedure. It is still unclear
whether concomitant administration of methotrexate
(MTX) may increase and prolong the effectiveness of IAC
injections.
Objectives
To compare the efficacy of IAC injection administered as
monotherapy or in association with MTX in children with
oligoarticular JIA in a phase II, randomized, actively
controlled, multicenter trial.
Methods
Inclusion criteria were oligoarticular JIA by ILAR criteria,
age < 18 years, and parent informed consent. Patients who
were previously treated with synthetic or biologic
DMARDs, had undergone an IAC injection < 3 months,
were newly injected only in 1 knee, or had active uveitis
were excluded. Patients enrolled were randomized 1:1 to
receive either IAC therapy alone (Arm 1) or IAC therapy
plus MTX (Arm 2). MTX was given orally at 15 mg/m2/
week (maximum 20 mg/week). All patients were followed
for 12 months and were assessed at 3, 6 and 12 months.
The primary outcome was synovitis flare, defined as
recurrence, persistence or new onset of synovitis in 1 or
more injected or uninjected (i.e. previously unaffected)
joints. Flare rate/probability was compared by chi-square
and Kaplan-Meier methods.
Results
A total of 207 patients (50 boys and 157 girls) were
enrolled, 102 in Arm 1 and 105 in Arm 2. Fifteen patients
lost to follow-up <6 months were included only in the
intention-to-treat (ITT) cohort. Patients in arms 1 and 2
were comparable for demographic features and median
number of injected joints (2 vs. 2). In the ITT cohort
(n=207) flare of synovitis occurred in 133 patients (64.2%),
69 (67.6%) in Arm 1 and 64 (60.9%) in Arm 2 (p=0.31),
whereas in the as-observed (AO) cohort (n=192) flare of
synovitis occurred in 118 patients (61.4%), 64 (66%) in
Arm 1 and 54 (56.8%) in Arm 2 (p=0.19). By Kaplan-
Meier analysis, the probability of synovitis flare in the
2 treatment arms was comparable in both ITT and AO
cohorts (log-Rank test: p=0.18 and 0.07, respectively).
However, among the 118 patients who flared in the AO
cohort, flare in injected joints occurred more frequently in
Arm 1 than in Arm 2 (46/64, 71.9% vs. 29/54, 53.7%;
p = 0.04).
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Conclusion
The association of oral MTX did not increase the overall
effectiveness of IAC therapy. However, flare of synovitis in
injected joints occurred less frequently in patients who
received concomitant MTX.
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